A new meta-analysis shows point-of-care testing reduces unnecessary antibiotics in patients experiencing COPD exacerbations, ...

jetMESSENGER ® reagent considerably outstrips Lipofectamine ™ 2000 transfection reagent in T cells, reaching more elevated GFP expression while preserving cell integrity. In B cells, it shows superior ...

Adoptive cell therapy based on ex-vivo expanded tumor-infiltrating lymphocytes (TILs) has historically been most effective in ...

A new study reveals the C-reactive protein-albumin-lymphocyte (CALLY) index is a strong predictor of long-term survival in ...

Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

Amtagvi® and its accompanying design marks, Proleukin ®, Iovance ®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

We are pleased to have the opportunity to present new data from the Phase 2 OVATION 2 Study of IMNN-001 in an oral presentation at ASCO’s Annual Meeting,” said Stacy Lindborg, Ph.D., president and ...

Specifically, its Amtagvi won an accelerated approval from the U.S. Food and Drug Administration (FDA) as a ...